{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T15:33:54Z","timestamp":1700840034266},"reference-count":10,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,15]]},"DOI":"10.1182\/blood.2022017344","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T16:38:24Z","timestamp":1671122304000},"page":"2529-2530","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["An unexpected partnership targeting <i>FLT3wt<\/i> AML"],"prefix":"10.1182","volume":"140","author":[{"given":"Thorsten","family":"Braun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"24","key":"2022121516375996400_bib1","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2022121516375996400_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2022121516375996400_bib3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"issue":"10","key":"2022121516375996400_bib4","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response\u00a0in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"7","key":"2022121516375996400_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2022121516375996400_bib6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"key":"2022121516375996400_bib7","doi-asserted-by":"crossref","first-page":"100672","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev"},{"issue":"18","key":"2022121516375996400_bib8","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2022121516375996400_bib9","article-title":"Venetoclax in combination with gilteritinib demonstrates molecular clearance of FLT3 mutation in relapsed\/refractory FLT3-mutated acute myeloid leukemia [abstract]","volume":"138","author":"Daver","year":"2021","journal-title":"Blood"},{"issue":"22","key":"2022121516375996400_bib10","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/24\/2529\/2023905\/blood-1020-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/24\/2529\/2023905\/blood-1020-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T16:38:32Z","timestamp":1671122312000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/24\/2529\/493450\/An-unexpected-partnership-targeting-FLT3wt-AML"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":10,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017344","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]}}}